Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients.
about
Granuloma formation in pulmonary sarcoidosisChemokines and chemokine receptors in arthritis.Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis.Screening for tuberculosis infection prior to initiation of anti-TNF therapy.Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humansA spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis.Successes and failures of chemokine-pathway targeting in rheumatoid arthritis.Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines.Galleria mellonella - a novel infection model for the Mycobacterium tuberculosis complexTargeted Screening for Latent TB Infection prior to Biologic Therapy to Improve Patient Safety and Reduce Costs: A Prospective Observational Study
P2860
Q26863703-CC439D75-5CCA-41BD-A30F-CDF3EB972CE9Q34051768-117911E9-B9B6-42BC-9812-96BE8E4116D6Q34388430-22917A7B-C43D-4CC6-9C87-241AF31F42A3Q36995803-5EB74AF4-6389-44FC-8000-F83D9786904EQ37170834-F36FB096-DA81-4C4F-B9C4-2469BC9E2E3FQ37857711-19BDEF67-8FC0-4262-B3F7-AF076E28D49EQ38647749-DDA482E9-B853-4BE9-A57F-11700472A7D0Q38977012-F99FF026-CE0F-486C-9F64-6793181AD546Q41686103-ACE98433-6F97-4DBD-8E50-730F6A05B9F8Q49508046-BA73CFA3-379D-4808-8150-82D846D28A3EQ50098937-8B30B0E7-117E-4965-90AC-E39D09BDECE6Q55287141-8763BBC8-F66E-4082-ACAB-8F7358E2826CQ58806135-107EA3EC-6D15-418D-8BD3-DDB744CB78F8Q59047425-0F3489DC-EEC1-4D9B-A09D-A3BBFD17FAF6
P2860
Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Reduction of chemokine secreti ...... n infliximab-treated patients.
@en
Reduction of chemokine secreti ...... n infliximab-treated patients.
@en-gb
Reduction of chemokine secreti ...... n infliximab-treated patients.
@nl
type
label
Reduction of chemokine secreti ...... n infliximab-treated patients.
@en
Reduction of chemokine secreti ...... n infliximab-treated patients.
@en-gb
Reduction of chemokine secreti ...... n infliximab-treated patients.
@nl
prefLabel
Reduction of chemokine secreti ...... n infliximab-treated patients.
@en
Reduction of chemokine secreti ...... n infliximab-treated patients.
@en-gb
Reduction of chemokine secreti ...... n infliximab-treated patients.
@nl
P2093
P2860
P50
P356
P1476
Reduction of chemokine secreti ...... n infliximab-treated patients.
@en
P2093
Adrian R Martineau
Beate Kampmann
Corinne Fisher
Geoffrey Pasvol
Sandra M Newton
Sarah L Mackie
Shouma Dutta
P2860
P304
P356
10.1128/CVI.00401-07
P577
2007-12-26T00:00:00Z